Prostate Neoplasms

Oncology
3
Pipeline Programs
3
Companies
50
Clinical Trials
4 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

J&
AKEEGAApproved
niraparib tosylate monohydrate and abiraterone acetate
Johnson & Johnson
oral2023

Competitive Landscape

3 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
AKEEGA(Abiraterone Acetate)N/A5 trials
Active Trials
NCT01217697Approved For Marketing
NCT05401214Approved For Marketing
NCT01834209No Longer Available
+2 more trials
Astellas
AstellasChina - Shenyang
1 program
1
ASG-5MEPhase 1
Pfizer
PfizerNEW YORK, NY
1 program
1
ASG-5MEPhase 11 trial
Active Trials
NCT01228760Completed46Est. Feb 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate
Johnson & JohnsonAbiraterone Acetate

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,031 patients across 50 trials

NCT02405858Johnson & JohnsonAbiraterone Acetate

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Start: Apr 2015Est. completion: Dec 201751 patients
Phase 4Completed
NCT03777982Johnson & JohnsonAbiraterone Acetate

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Start: Apr 2020Est. completion: Feb 202412 patients
Phase 3Terminated
NCT03903835Johnson & JohnsonAbiraterone Acetate

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Start: Feb 2019Est. completion: Dec 2026750 patients
Phase 3Recruiting
NCT03009981Johnson & JohnsonAbiraterone Acetate

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Start: Mar 2017Est. completion: Jun 2025504 patients
Phase 3Completed
NCT01957436Johnson & JohnsonAbiraterone Acetate

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

Start: Nov 2013Est. completion: Dec 20321,173 patients
Phase 3Active Not Recruiting
NCT01517802Johnson & JohnsonAbiraterone Acetate

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Start: Mar 2012Est. completion: Apr 202132 patients
Phase 3Completed
NCT06392841Johnson & JohnsonAbiraterone Acetate

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Start: Oct 2025Est. completion: Apr 20280
Phase 2Withdrawn
NCT06527690Johnson & JohnsonAbiraterone Acetate

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Start: Apr 2025Est. completion: Feb 20280
Phase 2Withdrawn
NCT06212583Johnson & JohnsonAbiraterone Acetate

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Start: Apr 2024Est. completion: Dec 202988 patients
Phase 2Recruiting
NCT04812366Johnson & JohnsonAbiraterone Acetate

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Start: Sep 2021Est. completion: Apr 2026315 patients
Phase 2Recruiting
NCT03902951Johnson & JohnsonAbiraterone Acetate

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Start: Mar 2021Est. completion: Jan 202828 patients
Phase 2Active Not Recruiting
NCT03999515Johnson & JohnsonAbiraterone Acetate

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Start: Apr 2020Est. completion: Jun 20213 patients
Phase 2Terminated
NCT03458247Johnson & JohnsonAbiraterone Acetate

Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer

Start: Jun 2018Est. completion: Dec 202194 patients
Phase 2Completed
NCT03431350Johnson & JohnsonAbiraterone Acetate

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Start: Mar 2018Est. completion: Dec 2025136 patients
Phase 2Active Not Recruiting
NCT02867020Johnson & JohnsonAbiraterone Acetate

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Start: Oct 2017Est. completion: Jun 2021128 patients
Phase 2Completed
NCT03098836Johnson & JohnsonAbiraterone Acetate

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Start: Jul 2017Est. completion: Jul 202493 patients
Phase 2Completed
NCT02849990Johnson & JohnsonAbiraterone Acetate

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Start: Mar 2017Est. completion: Dec 202022 patients
Phase 2Completed
NCT02903368Johnson & JohnsonAbiraterone Acetate

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Start: Oct 2016Est. completion: Jul 2024118 patients
Phase 2Completed
NCT02160353Johnson & JohnsonAbiraterone Acetate

Neo-adjuvant Abiraterone Prostate Study

Start: Jul 2015Est. completion: Jan 202145 patients
Phase 2Completed
NCT02217566Johnson & JohnsonAbiraterone Acetate

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Start: Sep 2014Est. completion: Oct 201846 patients
Phase 2Completed
NCT02036060Johnson & JohnsonAbiraterone Acetate

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

Start: Feb 2014Est. completion: Oct 2020119 patients
Phase 2Completed
NCT02025010Johnson & JohnsonAbiraterone Acetate

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Start: Jan 2014Est. completion: Apr 202560 patients
Phase 2Completed
NCT01717053Johnson & JohnsonAbiraterone Acetate

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Start: Jan 2014Est. completion: Aug 202137 patients
Phase 2Completed
NCT01946165Johnson & JohnsonAbiraterone Acetate

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Start: Oct 2013Est. completion: Jul 201769 patients
Phase 2Completed
NCT01867710Johnson & JohnsonAbiraterone Acetate

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Start: Jul 2013Est. completion: Jun 2018164 patients
Phase 2Completed
NCT01845792Johnson & JohnsonAbiraterone Acetate

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Start: Jul 2013Est. completion: Feb 20177 patients
Phase 2Terminated
NCT01814865Johnson & JohnsonAbiraterone Acetate

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Start: May 2013Est. completion: Dec 20130
Phase 2Withdrawn
NCT01637402Johnson & JohnsonAbiraterone Acetate

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Start: Mar 2013Est. completion: Feb 201741 patients
Phase 2Completed
NCT01424930Johnson & JohnsonAbiraterone Acetate

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Start: Oct 2011Est. completion: May 201325 patients
Phase 2Completed
NCT01685983Johnson & JohnsonAbiraterone Acetate

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Start: Aug 2011Est. completion: Mar 201882 patients
Phase 2Completed
NCT01381874Johnson & JohnsonAbiraterone Acetate

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Start: Aug 2011Est. completion: Aug 2018297 patients
Phase 2Completed
NCT01314118Johnson & JohnsonAbiraterone Acetate

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Start: May 2011Est. completion: Dec 2024131 patients
Phase 2Completed
NCT01254864Johnson & JohnsonAbiraterone Acetate

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Start: Mar 2011Est. completion: Dec 2023190 patients
Phase 2Completed
NCT01199146Johnson & JohnsonAbiraterone Acetate

Abiraterone Post Ketoconazole for Prostate Cancer

Start: Sep 2010Est. completion: Mar 201642 patients
Phase 2Completed
NCT00924469Johnson & JohnsonAbiraterone Acetate

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Start: Nov 2009Est. completion: Mar 201258 patients
Phase 2Completed
NCT00544440Johnson & JohnsonAbiraterone Acetate

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Start: Oct 2007Est. completion: Aug 201257 patients
Phase 2Completed
NCT06329830Johnson & JohnsonAbiraterone Acetate

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Start: Oct 2024Est. completion: Oct 20280
Phase 1/2Withdrawn
NCT04194554Johnson & JohnsonAbiraterone Acetate

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Start: Nov 2020Est. completion: May 2027102 patients
Phase 1/2Active Not Recruiting
NCT00473746Johnson & JohnsonAbiraterone Acetate

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

Start: Jun 2006Est. completion: Dec 201266 patients
Phase 1/2Completed
NCT05818683Johnson & JohnsonAbiraterone Acetate

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Start: Apr 2023Est. completion: Sep 2027277 patients
Phase 1Recruiting
NCT05295927Johnson & JohnsonAbiraterone Acetate

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start: Mar 2022Est. completion: Sep 20223 patients
Phase 1Terminated
NCT04662580Johnson & JohnsonAbiraterone Acetate

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Start: May 2021Est. completion: Dec 2026183 patients
Phase 1Active Not Recruiting
NCT04577833Johnson & JohnsonAbiraterone Acetate

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Start: Nov 2020Est. completion: Dec 2026136 patients
Phase 1Active Not Recruiting
NCT02913196Johnson & JohnsonAbiraterone Acetate

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Start: Dec 2016Est. completion: Oct 202616 patients
Phase 1Active Not Recruiting
NCT02924766Johnson & JohnsonAbiraterone Acetate

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Start: Oct 2016Est. completion: Jul 201934 patients
Phase 1Completed
NCT02230046Johnson & JohnsonAbiraterone Acetate

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

Start: Oct 2014Est. completion: Nov 2014102 patients
Phase 1Completed
NCT01897389Johnson & JohnsonAbiraterone Acetate

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

Start: Jul 2013Est. completion: Sep 201332 patients
Phase 1Completed
NCT01873001Johnson & JohnsonAbiraterone Acetate

A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants

Start: May 2013Est. completion: Jul 201316 patients
Phase 1Completed
NCT01678573Johnson & JohnsonAbiraterone Acetate

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

Start: Jul 2012Est. completion: Sep 201215 patients
Phase 1Completed
NCT01640093Johnson & JohnsonAbiraterone Acetate

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

Start: May 2012Est. completion: Jul 201232 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 6,031 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)